Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
74 studies found for:    Melanoma (women OR woman OR female)
Show Display Options
Rank Status Study
21 Recruiting Ipilimumab With or Without Dabrafenib, and/or Trametinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Drug: Dabrafenib;   Biological: Ipilimumab;   Drug: Trametinib;   Other: Laboratory Biomarker Analysis
22 Recruiting Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malignant Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: bevacizumab;   Drug: carboplatin;   Drug: everolimus;   Drug: paclitaxel
23 Active, not recruiting Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage III Melanoma;   Stage IV Melanoma
Interventions: Biological: ipilimumab;   Biological: sargramostim
24 Completed Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
Condition: Melanoma (Skin)
Interventions: Drug: carboplatin;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Genetic: protein expression analysis;   Other: immunoenzyme technique;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: biopsy
25 Completed Flavopiridol in Treating Patients With Metastatic Malignant Melanoma
Condition: Melanoma (Skin)
Intervention: Drug: alvocidib
26 Completed
Has Results
Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery
Conditions: Recurrent Melanoma;   Stage IV Melanoma
Interventions: Drug: sorafenib tosylate;   Drug: tipifarnib;   Drug: temsirolimus
27 Completed Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery
Condition: Melanoma (Skin)
Interventions: Biological: bevacizumab;   Drug: carboplatin;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Drug: temozolomide
28 Recruiting A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma
Conditions: Advanced Melanoma;   Metastatic Melanoma
Intervention:
29 Completed Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery
Condition: Melanoma (Skin)
Interventions: Drug: everolimus;   Drug: temozolomide;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: flow cytometry;   Other: immunohistochemistry staining method;   Other: immunologic technique
30 Active, not recruiting Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: polarized dendritic cells;   Biological: non-polarized dendritic cells
31 Completed The Incidence of Breast and Other Cancers Among Female Flight Attendants
Conditions: Thyroid Cancer;   Breast Cancer;   Non-Melanoma Skin Cancer;   Melanoma
Intervention:
32 Completed NIR-Guided Sentinel Lymph Node Mapping in Melanoma
Condition: Melanoma
Intervention: Procedure: Sentinel Lymph Node Mapping
33 Suspended Leflunomide+Vemurafenib in V600 Mutant Met. Melanoma
Condition: Melanoma
Interventions: Drug: Vemurafenib;   Drug: Leflunomide
34 Active, not recruiting Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma
Conditions: Acral Lentiginous Malignant Melanoma;   Lentigo Maligna Malignant Melanoma;   Nodular Malignant Melanoma;   Recurrent Melanoma;   Solar Radiation-related Skin Melanoma;   Stage IV Melanoma;   Superficial Spreading Malignant Melanoma
Interventions: Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097;   Other: laboratory biomarker analysis
35 Completed Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma
Condition: Metastatic Melanoma
Interventions: Drug: Vinorelbine;   Drug: Docetaxel;   Drug: Sargramostim
36 Completed SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma
Condition: Melanoma (Skin)
Intervention: Drug: ispinesib
37 Completed A Follow-up Study of Women Evaluated and Treated for Infertility
Conditions: Ovarian Cancer;   Breast Cancer;   Endometrial Cancer;   Thyroid Cancer;   Colrectal Cancer, Melanoma
Intervention:
38 Recruiting Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma
Condition: Metastatic Melanoma
Interventions: Biological: DC vaccine;   Drug: Dasatinib
39 Completed
Has Results
Abraxane and Avastin as Therapy for Patients With Malignant Melanoma, a Phase II Study
Condition: Metastatic Malignant Melanoma
Interventions: Drug: Avastin;   Drug: Abraxane
40 Recruiting Targeted Silica Nanoparticles for Image-Guided Intraoperative Sentinel Lymph Node Mapping in Head and Neck Melanoma, Prostate and Cervical/Uterine Cancer Patients
Conditions: Head and Neck Cancer;   Melanoma;   Prostate Cancer;   Cervical Cancer;   Uterine Cancer
Intervention: Drug: fluorescent cRGDY-PEG-Cy5.5-C dots

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years